Contact Information: For further information contact: David Carey Lazar Partners Ltd. 212-867-1768
Electro-Optical Sciences Provides MelaFind(R) Development Update
| Source: Electro-Optical Sciences, Inc.
IRVINGTON, NY--(Marketwire - December 29, 2008) - Electro-Optical Sciences, Inc. ("EOS")
(NASDAQ : MELA ), a medical device company focused on the design and
development of MelaFind®, a non-invasive, point-of-care instrument to
assist in the early detection of melanoma, today announced that the
algorithms for analysis of the MelaFind pivotal trial have been finalized.
"All follow-up data have been received, the pivotal trial sites have been
closed, and the databases are undergoing third-party statistical
validation. In addition, all image analysis algorithms including the
classification algorithms are final, and in accordance with FDA design
control requirements are undergoing software verification and validation.
This work is being conducted by expert third-party contract research
organizations and subcontractors. We look forward to unblinding the data
and announcing top-line results within the next several weeks," said Joseph
V. Gulfo, MD, MBA, President & CEO.
About Electro-Optical Sciences
EOS is a medical device company focused on designing and developing a
non-invasive, point-of-care instrument to assist in the early detection of
melanoma. MelaFind features a hand-held imaging device that emits light of
multiple wavelengths to capture images of suspicious pigmented skin lesions
and extract data. Using sophisticated algorithms, the data are then
analyzed against a proprietary database of melanomas and benign lesions in
order to provide information to the physician and produce a recommendation
of whether the lesion should be biopsied.
Melanoma is the deadliest of skin cancers, responsible for approximately
80% of all skin cancer deaths. Unless melanoma is detected early and
excised with proper margins, the patient survival rate is poor, as there is
currently no cure for advanced stage melanoma.
For more information on EOS, visit www.eosciences.com.
Safe Harbor
This press release includes "forward-looking statements" within the meaning
of the Securities Litigation Reform Act of 1995. These statements include
but are not limited to our plans, objectives, expectations and intentions
and other statements that contain words such as "expects," "contemplates,"
"anticipates," "plans," "intends," "believes" and variations of such words
or similar expressions that predict or indicate future events or trends, or
that do not relate to historical matters. These statements are based on our
current beliefs or expectations and are inherently subject to significant
uncertainties and changes in circumstances, many of which are beyond our
control. There can be no assurance that our beliefs or expectations will be
achieved. Actual results may differ materially from our beliefs or
expectations due to economic, business, competitive, market and regulatory
factors.